[8-K] Aardvark Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Aardvark Therapeutics disclosed via this Current Report that it issued a press release announcing new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. The company states the full text of the press release is filed as Exhibit 99.1 to the report and is incorporated by reference.

The filing does not include clinical data, quantitative results, financial statements, or a timetable for next steps; the report also identifies the registrant as an emerging growth company. Consult Exhibit 99.1 for the full press release text and any data not contained in the 8-K.

Insights

Biotech R&D Specialist

TL;DR: The company reported positive preclinical results for ARD-201 but provided no data in the 8-K; review Exhibit 99.1 for details.

The filing confirms Aardvark announced positive preclinical data for ARD-201 targeting metabolic obesity and related conditions. As presented, the 8-K serves primarily to attach and incorporate the press release rather than to disclose experimental details or metrics. For scientists or partners evaluating the program, the press release (Exhibit 99.1) must be reviewed to assess study design, endpoints, and statistical significance; the 8-K itself contains no such specifics.

Securities/Disclosure Analyst

TL;DR: The 8-K formally files a press release about ARD-201; it contains no financial information or quantified results within the report.

From a disclosure and investor-relations perspective, Aardvark used Item 8.01 to notify the market and incorporated the press release as Exhibit 99.1. The filing identifies the company as an emerging growth company and does not include financial statements, earnings data, or material quantitative results in the body of the 8-K. Investors and analysts should consult the referenced exhibit for substantive content; the 8-K itself is a cover filing.

0001774857false00017748572025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42513	82-1606367
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		AARD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 12, 2025, Aardvark Therapeutics, Inc. issued a press release announcing new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AARDVARK THERAPEUTICS, INC.
Date:	August 12, 2025	By:	/s/ Tien-Li Lee, M.D.
			Tien-Li Lee, M.D. Chief Executive Officer